FXN and Friedreich ataxia: In any case, it is very clear that for any frataxin-restoring treatment to successfully mitigate the neurological symptoms of FRDA, it must target structures that are beyond the BBB, either by using therapeutics that are able to cross into the CNS after systemic administration or by direct dosing into the brain parenchyma or in CSF.